主页 > 医药科学 >
【bio-news】辉瑞产品库:肿瘤药进,提升好胆固醇出
Pfizer’s Pipeline: Cancer’s In, Good Cholesterol’s Out
Posted by Avery Johnson
With a bit of hand-waving about its newfound fondness for transparency, Pfizer updated the public summary of its research pipeline this afternoon.
The highlights: A record 47 drug hopefuls in Phase II, 11 in Phase III, and 14 total biologics. Pfizer’s huge investment in cancer paid off with 20 potential medicines, the most being studied in any disease.
The lowlights: The number of drugs in Phase I fell over the past seven months, and 13 projects were abandoned. Pfizer has put on hold its backup compounds to torcetrapib, an experimental booster of good cholesterol that failed last year.
You can see the latest pipeline review here.
In what could be his last update on the behemoth’s science projects, outgoing research chief John LaMattina (pictured) sang the praises of the diverse Phase II candidates, comparing them to “a class of high-school freshmen before they develop into [adults], with pluses and minuses.” (It’s still unclear who will replace LaMattina; for speculation on who his successor will be, click here.)
When CEO Jeffrey Kindler took over last summer, he promised to be more open. In December, Pfizer first put its drug pipeline online in a step toward living up to that promise (and keeping up with other companies that already had theirs available for public viewing, without the PR push).
“That was Jeff’s mandate and this is as transparent in our pipeline as we’ve ever been,” LaMattina told the Health Blog this afternoon, just before the company updated its pipeline on its Web site. “As a research director, you’d like to hold in as much as possible. Our competitors look at this up and down … it’s the same thing I’m doing with other people’s pipelines.” 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-04 17:12
医学,生命科学网